不同剂量重组人类促红细胞生成素在早产儿贫血防治中的临床观察  

Clinical evaluation of recombinant human erythropoietin with different doses in prevention and treatment of anemia of premature infants

作　　者：刘金婷[1] 刘金和 张桂平 

机构地区：[1]北京市陆军航空兵学院门诊部,北京101123 [2]河北省衡水市桃城区妇幼保健院,河北衡水053000

出　　处：《转化医学电子杂志》2015年第4期1-2,共2页E-Journal of Translational Medicine

摘　　要：目的:观察不同剂量重组人类促红细胞生成素(rhEPO)对早产儿贫血的预防.方法:将88例早产儿随机分为两组,即小剂量组[300 U/(kg·w)]42例、大剂量组[750 U/(kg·w)]46例.出生后1周开始皮下注射rh-EPO,隔日1次,3次/周,共6周.两组患儿均于出生后肌肉注射维生素K1 1 mg/次.结果:疗程结束后小剂量组血红蛋白、网织红细胞、红细胞压积比大剂量组下降程度明显,输血率差异显著.结论:rh-EPO能预防早产儿贫血,大剂量[750 U/(kg·w)]效果显著,且安全有效.AIM： To research the preventional effect of recombinant human erythropoietin （rh-EPO） with different doses on anemia in premature infants. METHODS： The premature infants were divided randomly into two group, 42 cases in low dose group （300 U/kg？w）, 46 cases in high dose group （750 U/kg？w）. rh-EPO was injected subcutaneously 1 week after birth, once another day, 3 times per week, 6 weeks in all. All the infants in two groups were given vitamin K1 1mg/time with muscle injection, oral vitamin C 100mg/day. RESULTS： After the course of treatment, hemoglobin, reticulocyte and HCT decreased dramatically, the difference of blood transfusion between two groups was statistically significant. CONCLUSION： rh-EPO can prevent the anemia in premature infants and the high dose （750U/kg？w） is effective and safe.

关 键 词：重组人类促红细胞生成素 贫血 早产 

分 类 号：R722.6[医药卫生—儿科]